Press Release - January 14, 2016
Heidelberg, Germany, January 14, 2016 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that Dr. Andrew Evens has joined Affimed’s Scientific Advisory Board. Dr. Evens is Professor of Medicine at Tufts University School of Medicine and he is Chief of the Division of Hematology/Oncology and Director of the Tufts Cancer Center at Tufts Medical Center in Boston, Massachusetts. He was also named the Chan Soon-Shiong Endowed Scholar in Precision Medicine at Tufts Medical Center.
“We are pleased and honored to have added Dr. Evens to our Scientific Advisory Board,” said Jens-Peter Marschner, M.D., CMO of Affimed. “Dr. Evens brings invaluable expertise in the field of hematological malignancies, including translational work and clinical trial design, which will be extremely important as the Company moves forward towards mid-stage and registrational studies with its two lead pipeline candidates, which are currently in Phase II and Phase I trials.”
Dr. Evens completed his Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and The Robert H. Lurie Comprehensive Cancer Center (RHLCCC) where he also remained on faculty for approximately 15 years. Before arriving to Tufts Medical Center, he was a faculty member at the University of Massachusetts Medical School and the UMass Memorial Cancer Center where he served as the Deputy Director for the Cancer Center. Dr. Evens’ focus is in the biology, prognosis and treatment of Non-Hodgkin lymphoma and Hodgkin disease/lymphoma. He has designed and conducted a multitude of clinical trials in lymphoid malignancies and has authored or co-authored more than 100 original articles in this field. Dr. Evens also maintains a R01-funded translational lymphoma laboratory examining lymphoma biology, signal transduction pathways, free radical-mediated biology and the development of novel targeted agents for the treatment of lymphoma. Additionally, Dr. Evens is an Associate Editor for the British Journal of Haematology; he chairs the Hematology Panel for the VA R01 Scientific Merit Review committee; and he is a primary member of the Hodgkin Lymphoma Working Group for the NIH and NCI Steering Committee.
Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates our intellectual property position, our collaboration activities, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
Caroline Stewart, Head IR
Phone: +1 347 394 6793